Market
Major US Insurance Companies Refuse ENHERTU® Coverage for HER2-low by 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Statements or policy updates from major US insurance providers
Story
FDA Approves ENHERTU® for HER2-Low Breast Cancer, Showing 36% Risk Reduction and Hazard Ratio of 0.64
Jan 28, 2025, 12:04 AM
The U.S. Food and Drug Administration (FDA) has approved ENHERTU® (fam-trastuzumab deruxtecan-nxki) as the first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer. This approval is specifically for patients who have experienced disease progression following one or more endocrine therapies. Clinical data indicates that ENHERTU® demonstrated a 36% reduction in the risk of disease progression or death compared to chemotherapy, with a hazard ratio of 0.64 (95% confidence interval: 0.54-0.76; p<0.0001) in a trial involving chemotherapy-naïve patients with HER2-low or HER2-ultralow metastatic breast cancer. The approval marks a significant advancement in treatment options for this patient population, which previously had limited therapeutic alternatives.
View original story
Similar markets
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Rarely covered • 25%
Widely covered • 25%
Partially covered • 25%
Not covered • 25%
Anthem • 25%
Aetna • 25%
None • 25%
UnitedHealthcare • 25%
Other • 25%
Pfizer • 25%
Novartis • 25%
Roche • 25%
Improve Customer Service • 25%
Increase Transparency • 25%
Lower Premiums • 25%
No Significant Change • 25%